Choosing the largest device as the “worst-case” representative for cleaning validation may not adequately challenge the cleaning process. A more comprehensive, risk-based approach considers factors such as geometry, materials, surface finish, manufacturing processes, and post-clean operations, and Cretex Medical | QTS can help OEMs develop efficient validation strategies that meet evolving regulatory expectations.
September 22, 2026
Effective cleaning validation requires more than selecting the largest device as the “worst-case” representative; instead, it requires considering the full range of device, manufacturing, and post-clean characteristics to create a scientifically justified and regulatory-ready validation strategy.
In the world of medical device manufacturing, the term "worst-case" is used frequently. It is a cornerstone of process validation strategies. The logic seems simple. If you can demonstrate that your cleaning process works on the most difficult-to-clean device in a product line, you can safely assume it works for every other device in that cleaning family. This approach is intended to improve validation efficiency by minimizing sample quantities and testing. However, there is a common and dangerous misconception about what actually constitutes a worst-case scenario.
For many original equipment manufacturers (OEMs), the default strategy is to select the largest device in a product family as the worst-case representative. The assumption is that the most surface area means the most difficult to clean. While that sounds intuitive, it’s often a fundamental mistake. In 2026, the FDA and other international notified bodies are looking far beyond just surface area. They are looking at the specific device features that challenge the cleaning process.
Use of a single device attribute (i.e. size) to evaluate a cleaning family is a leading cause of audit findings. More importantly, it presents a real risk to patient safety. Cretex Medical | QTS has the expertise and thorough industry experience to help OEMs build a validation that protects patients and stands up to scrutiny. We can guide the process beyond the biggest-is-hardest mindset with a more sophisticated approach to family grouping.
There are, of course, many considerations associated with choosing a representative device. These are some of them.
When an OEM incorrectly identifies the worst-case device, the validation is built on a risky foundation. This often comes to light during regulatory audits. Inspectors will look for the scientific justification behind family groupings. Auditors have a checklist built from standards like ISO 19227 and ASTM F3127, and if an OEM cannot explain why size was the only consideration in worst-case assignment, they will likely face a finding.
If the master device selection is not truly representative, the cleaning process may not be adequately challenged, which can lead to failure in the biocompatibility study. If these failures occur after the manufacturing process has been frozen, it can lead to months of redesign and re-testing, resulting in loss of potential revenue.
One way to overcome the challenges of choosing a representative device from the list of devices within the product family is to use a simulated device. The design of a simulated device includes all worst-case considerations and incorporates them into a single device.
For example, if a product family contains some devices with deep blind holes and other devices with porous coatings, a simulated device can be designed to include both. By testing this Frankenstein part, you create a challenge that is more rigorous than any single product in your catalog. This approach demonstrates a proactive, risk-based mindset.[MH1.1][AG1.2] It allows the OEM to cover a much broader range of products under a single validation protocol and mitigate regulatory risk.
QTS plays an active role in shaping the very standards that govern this industry. By participating in ISO, AAMI, and ASTM working groups, we stay at the forefront of regulatory changes, so we use the most current information to justify the validation strategy. This future-proofs your validation against the evolving expectations of 2026 and beyond.
To be successful in today’s regulatory environment, medical device manufacturers must adopt a more technical and data-driven approach to family grouping. With that, the cleaning validation should demonstrate that the process is capable of consistently reducing residues for ALL components in a product family. Working with an experienced partner like Cretex Medical | QTS allows you to tap into years of expertise in medical device cleaning and regulatory strategy to build a validation that is both efficient and robust. We’re here to help customers select the correct worst-case device and guide you through the cleaning validation process. We can work together to avoid the costs that come from over-testing and delayed product launches while ensuring your products are safe for the patients who rely on them.
Contact us today to start building a validation strategy that looks beyond the standard and secures the future of your product line.
Please visit our website for more information about Cretex Medical | QTS and our services.